Sign in
Taking people in South KoreaPhase 3

Testing Cilostazol and Ginkgo Leaf Extract for Memory in Older Adults With Diabetes

Tests cilostazol with ginkgo leaf extract against placebo in older adults with type 2 diabetes.

Key facts

Who runs it
Seoul National University Bundang Hospital
Where
Seongnam-si, South KoreaSee the site
Trial code
Registry title
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
Status
Recruiting
Phase
Phase 3
People taking part
80 people, planned
Started
1 Jan 2025
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cilostazol / Ginko Leaf Dried Ext.
  • Placebo
Record updated
25 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 60 or older with type 2 diabetes and mildly lowered memory and thinking test scores. It tests cilostazol with ginkgo leaf extract.

Age
60 years or older
Sex
All sexes can join.
Disease stage
Type 2 diabetes with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months.
Earlier treatment
Cannot have taken medicines that may affect thinking and memory within 3 months before screening.

Main reasons for not taking part

  • Type 1 diabetes, diabetic ketoacidosis, or diabetic coma or precoma
  • Poorly controlled blood sugar (HbA1c above 10.0% (86 mmol/mol))
  • MMSE score below 24, or a diagnosis of dementia such as Alzheimer's disease
  • Needing other blood-thinning or antiplatelet medicine
  • Severe depression, or alcohol or drug abuse within 1 year before screening

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients diagnosed with type 2 diabetes mellitus
  • Adults aged 60 years or older
  • Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months

Who cannot take part

  • Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
  • Patients with a history of alcohol or drug abuse within 1 year prior to screening
  • Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
  • Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
  • Patients diagnosed with dementia (e.g., Alzheimer's disease)
  • Patients with suspected cognitive impairment due to other causes
  • Patients with severe infections, recent surgery (perioperative status), or major trauma
  • Patients with pituitary or adrenal insufficiency
  • Patients with other medical conditions requiring hospitalization
  • Patients with poorly controlled blood glucose (HbA1c > 10.0%)
  • Patients with an MMSE score below 24
  • Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
  • Patients with severe depression
  • Patients deemed by the investigator to be otherwise unsuitable for study participation

Where in South Korea

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Soo Lim Dr., MD PhDTaking people

About the trial

What the trial wants to find out

This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.

The 2 groups in the trial

  • Cilostazol & Ginko Leaf Dried Ext.Treatment being tested

    Renexin CR tab (cilostazol 200mg / Ginko Leaf Dried Ext. 160mg)

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes
Plain-language title
Testing Cilostazol and Ginkgo Leaf Extract for Memory in Older Adults With DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 May 2025